Stock Price & Analysis

Analysis and Insights

Event Impact Assessment:

Purple Biotech Ltd. (PPBT) recently announced a registered direct offering of 472,668 American Depositary Shares (ADSs) at $6 per ADS, aiming to raise approximately $2.8 million to support oncology therapeutic development and corporate purposes. This announcement led to a significant market reaction, with the stock price dropping 28.57% to $6 in pre-market trading on the Nasdaq.

Stock Performance:

• Price Trend: PPBT's stock has shown high volatility, with a 60.75% decrease over the past year but a 182.83% increase in the last month.
• Current Price: As of March 25, 2025, PPBT's price is $2.69, near its 52-week low of $2.00.

Valuation Analysis:

• Market Cap: PPBT's market capitalization is relatively small, which can contribute to higher volatility.
• Price Movements: The stock's recent surge and drop indicate sensitivity to news and announcements.

Conclusion:

Given the significant volatility and recent price drop following the offering announcement, it may be prudent to sell PPBT stock if you are risk-averse. However, if you believe in the company's long-term potential in oncology therapeutics, holding could be an option.

I apologize, but I couldn't find relevant data to provide a specific price prediction for PPBT stock in 2025. For a more accurate analysis, please provide additional details or check back later when more information is available.

The S1 support level for PPBT Stock is $2.66 ,The R1 resistant level for PPBT Stock is $2.97.

As of the end of day on 2025-03-28, the price of PPBT Stock was $2.78.

The market cap of PPBT is $1.5B.

Analysis and Insights

To determine whether Purple Biotech Ltd (PPBT) is overvalued, we analyze its financial metrics, recent news, and market performance.

Valuation Metrics:

PPBT's valuation metrics are limited due to insufficient data, but the following points are notable:

• Price-to-Earnings (P/E) Ratio: Not available due to lack of earnings data.
• EV/EBITDA: 87.51 for Q2 2024 and 69.29 for Q3 2024, indicating high valuation relative to earnings.
• Price-to-Sales (P/S) and Price-to-Book (P/B): Not available due to missing data.

Recent News and Market Reaction:

• Direct Offering Announcement: PPBT announced a $2.8 million ADS offering at $6 per ADS, causing a 28.57% drop in pre-market trading.
• Stock Performance: The stock has seen significant volatility, with a 60.75% decrease over the past year but a 182.83% increase in the last month.

Financial Health:

• Revenue and Earnings: No revenue or earnings data available for 2024, raising concerns about the company's financial stability.
• Proceeds Usage: Funds from the ADS offering are intended for oncology therapeutic development and corporate purposes, but the market reaction suggests investor skepticism.

Conclusion:

Based on the available data, PPBT appears overvalued due to high EV/EBITDA ratios, lack of revenue growth, and significant stock price volatility. Investors should exercise caution and await more stable financial data before considering investment.

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

PPBT stock is predicted to reach $15 by 2030, driven by its promising oncology therapeutic pipeline and potential market growth. The stock's current volatility and recent offering-related drop are expected to stabilize as the company advances its treatments.

PPBT has a total of 20 employees.